Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "PYY Peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Peptide YY (PYY) also known as peptide tyrosine tyrosine is a peptide that in humans is encoded by the PYY gene. Peptide YY is a short (36-amino acid) peptide released from cells in the ileum and colon in response to feeding.
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
InactiveUS7166575B2Improved pharmacokineticImproved pharmacodynamic resultPowder deliveryPeptide/protein ingredientsDiseaseHypodermoclysis
Pharmaceutical compositions and methods are described comprising at least one peptide YY compound and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of peptide YY to the blood plasma or central nervous system (CNS) tissue or fluid, for example, by yielding a peak concentration (Cmax) of the peptide YY in the blood plasma or CNS tissue or fluid of the subject that is 20% or greater compared to a peak concentration of the peptide YY in the blood plasma or CNS tissue or fluid of the subject following administration to the subject of a same concentration or dose of the peptide YY to the subject by subcutaneous injection.
Owner:MDRNA
Anti-obesity agents
InactiveUS20050176643A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.
Owner:CONJUCHEM
Compositions for delivering peptide yy and pyy ag0nists
ActiveUS20110183898A1Reduce deliveryImprove bioavailabilityOrganic active ingredientsBiocideAntigenPYY Peptide
The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.
Owner:NOVO NORDISK AS
Compositions for delivering peptide YY and PYY agonists
InactiveUS20050009748A1Reduce deliveryImprove bioavailabilityBiocideOrganic active ingredientsPYY PeptideAgonist
The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake
Owner:NOVO NORDISK NORTH AMERICA OPERATIONS AS
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
InactiveUS7157426B2PromotePrevent and cure diabetesBiocideNervous disorderBinding peptideDense Core Vesicles
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
Owner:MDRNA
Compositions for enhanced epithelial permeation of peptide yy for treating obesity
InactiveUS20070275893A1Promote absorptionImprove bioavailabilityBiocideOrganic active ingredientsPYY PeptidePYY receptors
Owner:NASTECH PHARMA
Methods of using a g protein-coupled receptor to identify peptide yy (PYY) secretagogues and compounds useful in the treatment of conditions modulated by pyy
InactiveUS20090253153A1Improve the level ofDetectable level of constitutive activityNervous disorderBacteriaGPR119Malabsorption
The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
Owner:ARENA PHARMA
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
InactiveUS7229966B2Induce satiety in an individualPromote weight-loss in an individualBiocideNervous disorderDiseasePYY Peptide
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
Owner:MDRNA
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
InactiveUS7186691B2Induce satiety in an individualPromote weight-loss in an individualBiocideOrganic active ingredientsDiseaseBinding peptide
Owner:MDRNA
Compounds for control of appetite
This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.
Owner:CINCINNATI UNIV OF
Peptide Yy Analogues
InactiveUS20070244041A1Energy consumptionConvenient treatmentHormone peptidesPeptide/protein ingredientsCross-linkPYY Peptide
Analogues of the peptide PYY (1-36) are described in which the tertiary structure of the peptide is preserved and stabilised particularly to enhance binding and activation of the Y2 receptor by the use of cross links or rigid bends in the peptide to constrain conformationally the positions of the N-terminal part of the peptide sequence and amino acid 34. The analogues are useful in the control of food intake.
Owner:RHEOSCI
Novel Anti-Obesity Agents
InactiveUS20080194486A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide
Owner:CONJUCHEM
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
InactiveUS7186692B2Induce satietyPromoteHormone peptidesPeptide/protein ingredientsDiseaseBinding peptide
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
Owner:MDRNA
Peptide yy analogs
InactiveUS20060211610A1Promote weight gainEasy maintenanceBiocidePeptide/protein ingredientsPYY PeptidePYY receptors
The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.
Owner:IPSEN PHARMA SAS
Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
Owner:GARVAN INST OF MEDICAL RES
Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor
InactiveUS20100143934A1Lower Level RequirementsImprove the level ofAnimal cellsImmunoglobulins against animals/humansBiologyPathology diagnosis
The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease / disorder of bone tissue.
Owner:GARVAN INST OF MEDICAL RES
Compounds and their effects on feeding behaviour
InactiveUS8901073B2Reduction of appetiteReduction of food intakeHormone peptidesPeptide/protein ingredientsDiabetes mellitusCalorie intake
Owner:IMPERIAL INNOVATIONS LTD
Peptide yy formulations having increased stability and resistance to microbial agents
InactiveUS20070213270A1Strong risk factorHigh incidenceOrganic active ingredientsBiocideMicrobial agentCyclodextrin
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY (PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) wherein the formulations have increased resistance to microbial contamination and is comprised of a Y2 receptor-binding peptide, water, a cyclodextrin and sodium benzoate.
Owner:NASTECH PHARMA
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
InactiveUS20130316370A1Eliminate needEasy to adaptDisease diagnosisBiological testingWhite blood cellPancreatic hormone
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Follistatin, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1 / Keratin-10, Type II cytoskeletal Keratin-6A / 6B / 6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.
Owner:ASTUTE MEDICAL
Compositions for delivering peptide yy and pyy agonists
InactiveUS20160296599A1Reduce deliveryImprove bioavailabilityPeptide/protein ingredientsMetabolism disorderPYY PeptideNutrition
The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake.
Owner:NOVO NORDISK NORTH AMERICA OPERATIONS AS
Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
Owner:JANSSEN PHARMA NV
Satiation peptides for weight loss and altered taste sensitivity
ActiveUS20170326257A1Reduce riskReduce weightPeptide/protein ingredientsPharmaceutical delivery mechanismSatiationsPYY Peptide
The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and / or altered lipid taste sensitivity, as well as for the treatment of diabetes.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Noninvasive screening method for the detection of colorectal cancer
Disclosed is a method for the detection of colon cancer by a blood test for elevated levels of peptide YY (PYY), a hormone which is produced in the gut, secreted into blood and transported into the brain where it regulates appetite. Other body fluids can also be evaluated in the same way. The use of PYY measurement as part of the periodic medical examination together with other screening tests such as fecal hemoccult and carcinoembryonic antigen could substantially improve the possibility of diagnosis of colon cancer at an early stage when surgery is likely to be curative.
Owner:COREY ELIAS J
Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders
InactiveUS20130023466A1Modulate nutrient availabilityReduced availabilityHormone peptidesPeptide/protein ingredientsDiabetes mellitusPYY Peptide
Owner:ASTRAZENECA PHARMA LP
Formulations for enhanced mucosal delivery of pyy
Pharmaceutical formulations are described for enhancing mucosal delivery of peptide YY (PYY) to a mammal. A PYY dosage form is described that is suitable for multi-use administration. The PYY dosage form comprises a bottle containing an aqueous pharmaceutical formulation and an actuator effective intranasal administration of the formulation. The formulation comprises a therapeutically effective amount of PYY, a buffer to control pH, a water-miscible polar organic solvent and a chelating agent for cations. The PYY dosage form exhibits at least 90% PYY recovery after storage as used for greater than about five days.
Owner:MDRNA
Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
PendingCN112004822AEasy to understandPeptide/protein ingredientsMetabolism disorderCyclic peptideDisease
The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
Owner:JANSSEN PHARMA NV
Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
Owner:JANSSEN PHARMA NV
Methods of using a g protein-coupled receptor to identify peptide yy (PYY) secretagogues and compounds useful in the treatment of conditions modulated by pyy
InactiveUS20100203556A1Improve the level ofDetectable level of constitutive activityNervous disorderBacteriaGPR119Malabsorption
The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.
Owner:ARENA PHARMA
Piscine-derived pyy peptides for use in treating a metabolic disorder
PendingUS20210228679A1Increased proliferationEasy to usePeptide/protein ingredientsMetabolism disorderDiabetes mellitusPYY Peptide
The present invention relates to peptides for use in the treatment of metabolic disorders. In particular, the present invention relates to peptides for use in the treatment of diabetes. According to the present invention, there is provided a peptide for use in the treatment of a metabolic disorder; wherein the peptide is a piscine-derived PYY or fragment or analogue thereof.
Owner:UNIVERSITY OF ULSTER
Satiation peptides for weight loss and altered taste sensitivity
ActiveUS11311633B2Reduce riskReduce weightPeptide/protein ingredientsPharmaceutical delivery mechanismDiabetes mellitusPYY Peptide
The present application provides methods and compositions for AAV-mediated delivery of PYY and Glucagon-like Peptide 1 or an analog thereof (e.g., Exendin-4) to a subject (e.g., the saliva of a subject). In some embodiments, compositions and methods for topical delivery of Ex-4 and PYY peptides also are provided. Methods and compositions are useful to promote weight loss and / or altered lipid taste sensitivity, as well as for the treatment of diabetes.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com